The FDA has delayed a promised review of safety data for the abortion drug mifepristone at Commissioner Marty Makary’s request to put it off until after the midterm elections, according to sources https://t.co/0xWnJb1kge ...

The FDA’s routine approval of a second generic version of the abortion pill mifepristone has become the latest flashpoint in the fight over reproductive rights, @lisamjarvis says (via @opinion) https://t.co/yF3mUZCW5o ...

From @WSJopinion: The FDA’s approval of a generic version of mifepristone means more mail-order abortion, more women harmed, and more unborn children lost. This is a profound betrayal of the pro-life movement that elected Trump, writes @Mike_Pence. https://t.co/NdQuVJTPe3 ...

Group 1 - Kenvue, the maker of Tylenol, is facing backlash due to unsupported claims linking its product to autism, which may lead to further scrutiny of other medications [1] - Robert F. Kennedy Jr. is leveraging his position to push unverified health claims into public policy, impacting access to various medications [1][2] - Kennedy's "Make America Healthy Again" initiative targets multiple drugs, including antidepressants and statins, raising concerns about their safety and necessity [3][4] Group 2 - The initiative aims to assess the risks associated with selective serotonin reuptake inhibitors, which are used by approximately 11% of the population for mental health issues [3] - Statins, prescribed to over 92 million Americans, are also under scrutiny despite evidence supporting their safety and effectiveness in preventing heart disease [4] - Kennedy's organization has published articles questioning the efficacy of cholesterol-related treatments, suggesting they are overprescribed [5] Group 3 - Newer diabetes and obesity treatments, such as GLP-1s, are also being criticized by Kennedy, who has made false claims about their marketing and effectiveness [6][7] - A proposal to have Medicare cover GLP-1 drugs for obesity was rejected, potentially limiting access for 7 million Americans [8] - Kennedy's rhetoric suggests a broader agenda against pharmaceutical companies and their products, raising concerns about future restrictions on various medications [1][8]

Pharmaceutical Industry Pressure - Faith-based activists pressured Costco regarding mifepristone availability [1] - The group is now targeting CVS and Walgreens [1] Abortion Pill (Mifepristone) - Activists are specifically concerned about the abortion pill mifepristone [1] Retail Pharmacy Implications - Pharmacies like Costco, CVS, and Walgreens are facing pressure related to abortion pill offerings [1]

Industry Pressure - Faith-based activists pressured Costco to not offer mifepristone in its pharmacy locations [1] - The group is now focusing on CVS and Walgreens [1]

Industry Pressure - Faith-based activists previously pressured Costco regarding the abortion pill mifepristone [1] - The group is now focusing on CVS and Walgreens [1]

Pharmaceutical Industry & Social Activism - Faith-based activists pressured Costco to not offer mifepristone (abortion pill) in its pharmacies [1] - The activist group is now focusing on CVS and Walgreens regarding the abortion pill mifepristone [1]

A coalition of faith-based activists had pressured Costco to not offer the abortion pill mifepristone in its pharmacy locations. The group now turns its focus to CVS and Walgreens https://t.co/onQcBjz7pU ...

Drug Safety Review - The Health and Human Services Secretary requested a review of data on methapristone (abortion pill) [1] - The review is ongoing as part of a risk evaluation and mitigation strategy (REMS) commitment [2] - The review includes examining self-reported data in the adverse event reporting database [2] - The review also considers studies suggesting potential safety signals in large administrative databases, such as drug-drug interactions [3] Access to Medication - The company has no plans to change access to methapristone [3]